Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL vs DHA-PPQ for Malaria in Cameroonian Children
NCT05340153Phase 4
Key facts
- Status
- Unknown
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Sponsor
- University of Yaoundé I
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Conditions
- Plasmodium falciparum malaria
01
Overview
Phase 4, randomised, open-label trial of dihydroartemisinin and piperaquine in Plasmodium falciparum malaria, sponsored by University of Yaoundé I. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Children aged 6 months to 10 years with uncomplicated P. falciparum malaria and parasite density between 1000-200000/µl.
04
Registry description
Malaria is an infectious disease transmitted by the bite of an infected female anopheles mosquito. The most vulnerable group that bears the highest disease burden includes children less than five years and pregnant women. Artemether-lumefantrine (AL) has been used for the treatment of uncomplicated Plasmodium falciparum in Cameroon since 2006. In 2020, the government of Cameroon also adopted the use of dihydroartemisinin-piperaquine (DHA-PPQ) as one of the first line drugs for the treatment of malaria. Globally, several studies among children have reported high efficacy and safety of…
Beyond the preview
Go deeper on NCT05340153.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340153.